It has been over three decades since anthracyclines took their place as the standard
chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of …

The androgen receptor (AR) is expressed in the majority of breast cancer and across the
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …

Background Lung squamous cell carcinoma (LUSC) patients are often diagnosed at an
advanced stage and have poor prognoses. Thus, identifying novel biomarkers for the LUSC …

Breast cancer is the second most common malignancy in females worldwide and poses a
great challenge that necessitates the identification of novel therapeutic agents from several …

Abstract Background Topoisomerase II alpha (TOP2A) protein has been shown to be a
proliferation marker associated with tumor grade and Ki67 index. The prognostic effect of …

A recent analysis using family history weighting and co-observation classification modeling
indicated that BRCA1 c. 594-2A> C (IVS9-2A> C), previously described to cause exon 10 …

Topoisomerases are ubiquitous enzymes involved in maintaining genomic stability of the
cell by regulating the over-or underwinding of DNA strands. Besides their customary …

Despite the advances in diagnostic imaging and treatment modalities, the risk stratification
and final outcomes in patients with nasopharyngeal carcinomas (NPC) still remain …

Background Measurement of residual disease following neoadjuvant chemotherapy that
accurately predicts long-term survival in locally advanced breast cancer (LABC) is an …

Expression of the Topoisomerase II Alpha (TOP2A) Gene in Lung Adenocarcinoma Cells and
the Association with Patient Outcomes - PMC Back to Top Skip to main content NIH NLM Logo …